Senores Pharmaceuticals IPO Review

Senores Pharmaceuticals is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Senores Pharmaceuticals is currently developing niche, complex and specialty pharmaceuticals products.

The Company is promoted and managed by a team of professionals under the leadership of Swapnil Jatinbhai Shah (Promoter & Managing Director) - MBA form Hofstra University, New York & has experience of more than 15 Years in Pharmaceuticals Industry, Chetan Shah (Whole Time Director & Chief Operating Officer) - Experience of more than 24 Years & Deval Shah (Whole Time Director and Chief Financial Officer) - Chartered Accountant who has vast experience of more than 40 Years.

The Revenues from operations for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 1,833.53 Million, ₹ 2,173.42 Million, ₹ 390.21 Million and ₹ 146.31 Million respectively. The EBITDA for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 469.08 Million, ₹ 444.08 Million, ₹ 163.54 Million, and ₹ 24.13 Million, respectively. The Profit after Tax for the period ended on Sep 30, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 239.43 Million, ₹ 327.08 Million, ₹ 84.33 Million, and ₹ 9.91 Million respectively. This indicates steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹12.21 and post-issue EPS of ₹7.10 for FY24. The pre-issue P/E ratio is 32.02x, while the post-issue P/E ratio is 55.05x against the Industry P/E ratio is 39x. The company's ROCE for FY24 is 11.73%, ROE for FY24 is 23.60% and RoNW 23.60%. The Annualised EPS based on the latest financial data is ₹14.4 and PE ratio is 27.15x. These metrics suggest that the IPO is fairly priced.

The Grey Market Premium (GMP) of Senores Pharmaceuticals showing potential listing gains of 45.01%. Given the company's financial performance and the valuation of the IPO, we recommend Investors to Apply to the Senores Pharmaceuticals Limited IPO for Listing gain.

Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 

About the Author
 CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms during the training period. He is good at Technical analysis and Fundamental Analysis and uses both Technical and Fundamental analysis along with five other important factors that affect the movement of the Market namely Global Market Analysis, Upcoming Event Analysis, Institutional Money Analysis, Derivative Data Analysis, and Emotions and Sentiment of Traders and Investors in his Framework called - Technical Fundamental GUIDE to find the winning Trades.
You can connect with the Author on Telegram, YouTube and Website.